Restasis®
(Cyclosporine Ophthalmic Emulsion) 0.05%

CONFIDENCE in Coverage



89% of Medicare Part D patients have **unrestricted access**[1,*]



Are your patients getting the #1 dispensed branded eye drop when filled?

*Data for RESTASIS® only; does not include *RESTASIS MultiDose®*; as of Feb 2021.

Formulary coverage comparisons are not intended to imply a comparison of efficacy, safety, therapeutic equivalence, or overall cost of care.

Indications and Usage
RESTASIS® and *RESTASIS MultiDose®* ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information
Contraindications
RESTASIS® and *RESTASIS MultiDose®* are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Please see additional Important Safety Information on the reverse side.

Most commercially insured patients

pay as little as $0* for a 90-day supply

Important Safety Information (continued)
Warnings and Precautions
Potential for Eye Injury and Contamination: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination.

Use With Contact Lenses: RESTASIS® and *RESTASIS MultiDose®* should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and *RESTASIS MultiDose®* ophthalmic emulsion.

Adverse Reactions
In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see accompanying full Prescribing Information for RESTASIS® and *RESTASIS MultiDose®*.

*Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. This offer is not valid for patients enrolled in Medicare, Medicaid, or other state or federal healthcare programs.

The actual savings on your out-of-pocket costs for RESTASIS® or *RESTASIS MultiDose®* will vary according to refill quantity and personal healthcare insurance coverage.

Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with the applicable insurer. Allergan® does not endorse any individual plans.

Reference: 1. Managed Markets Insight & Technology, LLC, database as of Feb 2021.

Allergan an AbbVie company

Scan to start saving

Restasis®
(Cyclosporine Ophthalmic Emulsion) 0.05%